Protocol Ledger

NCT05308472 · Phase II · COMPLETED

Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP

Interventional Phase II clinical trial protocol NCT05308472 sponsored by Disc Medicine in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-10-31 Enrollment: 75 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05308472
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)75 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05308472
Protocol FieldVerified Registry Value
NCT IdentifierNCT05308472
Consolidated Lead SponsorDisc Medicine
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment75 participants (ACTUAL)
Registered Start Date2022-10-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI